ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00982319
Recruitment Status : Completed
First Posted : September 23, 2009
Results First Posted : July 31, 2018
Last Update Posted : July 31, 2018
Sponsor:
Collaborator:
Breast Cancer Research Foundation
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:
The purpose of this research is to examine the effect of a broccoli sprout preparation on specific factors in breast tissue that are related to breast cancer risk and to assess whether sulforaphane a key component of broccoli sprouts increases the levels of protective enzymes in breast tissue. In addition, the investigators will also examine how acceptable the broccoli sprouts preparation is to the study participants.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Broccoli sprout extract Drug: Mango juice Phase 2

Detailed Description:

A double-blind randomized Phase II chemoprevention trial of BSE versus placebo will be conducted in up to 35 women diagnosed with DCIS on core biopsy prior to their definitive surgery (study diagram below). The primary study endpoint will be a decrease in the mean proliferative rate measured by Ki67%.

Women diagnosed with DCIS on core or incisional/excisional biopsy scheduled for definitive surgery at Johns Hopkins Hospital will be recruited for this study. Participants will be placed on a cruciferous free diet for the 14 days prior to their surgical date and drink a randomized intervention beverage (mango juice with or without broccoli sprout extract). Additionally participants will provide 2 blood and 2 urine sample collections, report medication use and adverse events using prepared forms and complete a daily diet check list during the 14 day intervention. On the day of definitive breast surgery, 1-2 grams of breast tissue (including normal adjacent breast tissue) will be collected during surgery.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Evaluating the Effect of Broccoli Sprouts (Sulforaphane) on Cellular Proliferation, an Intermediate Marker of Breast Cancer Risk
Study Start Date : April 2009
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Broccoli sprout extract
Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
Drug: Broccoli sprout extract
100 µmols of sulforaphane (dissolvable)

Drug: Mango juice
150 mL of mango juice

Placebo Comparator: Mango juice
Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
Drug: Mango juice
150 mL of mango juice




Primary Outcome Measures :
  1. Absolute Change in Mean Proliferative Rate Measured by Ki67% [ Time Frame: Change from baseline to 14 days post-intervention ]
    Pathologists score the slides without knowledge of treatment assignment at the end of the study. All pre-post samples from one individual will be evaluated together. Quality control for these stains is performed routinely in the immunohistochemistry lab (using lymphoid tissue for Ki67). Initial scoring is performed where possible on a minimum of 3000 cells, by counting the number of positive cells divided by the total number of cells. DCIS lesions will be scored separately to adjacent normal tissue. The rationale for selecting Ki67 as a measure of cellular proliferation includes the robustness of the staining reaction, correlation with the S phase fraction of the cell cycle and mitotic index and that it can be successfully ascertained from core breast biopsies provided there is an adequate yield of epithelial cells. A negative value reflects a decrease in ki67 positive cells, therefore a decrease in cellular proliferation.


Secondary Outcome Measures :
  1. Phase II Protein Expression Levels of Cytoprotective Enzymes Known to be Modulated by Sulforaphane as Well as Morphological Changes in DCIS Specimens [ Time Frame: Change from baseline to 14 days post-intervention ]
    Cytoprotective enzymes (NQ01 and AKR1C1 expression) based on immunohistochemical stains and qualitative assessment of morphological changes determined by study pathologists blinded to outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female 18 + years of age
  • Confirmed diagnosis of DCIS on core or excisional/incisional biopsy and scheduled for definitive surgery
  • Pre or Post menopausal women reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months to eligibility screening
  • Agree to avoid cruciferous vegetable/condiment intake for 14 days
  • Agree to sign an informed consent and allow use of some tissue (slides) from biopsy and definitive surgery for research purposes

Exclusion Criteria:

  • Prior cancer diagnosis other than non-melanomatous skin cancer or cervical carcinoma in-situ
  • Used hormone replacement therapy, tamoxifen or raloxifene within the past 6 months prior to eligibility screening
  • Used antibiotics within 10 days prior to beginning cruciferous free diet (day -14 prior to surgery)
  • Smoked within the past 12 months prior to eligibility screening;
  • Active infection or inflammation of the breast at time of eligibility screening
  • Has baseline comprehensive metabolic panel (CMP) [Glucose, Calcium, Albumin, Serum total protein (TP), Sodium, Potassium, Carbon dioxide, Chloride, Blood urea nitrogen (BUN), Creatinine, Alkaline phosphatase (ALP), Alanine amino transferase (AST), Aspartate amino transferase (SGOT), and Bilirubin], prothrombin time (PT) and , complete blood count (CBC) values that are 1.5 times in either direction the reported normal range

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00982319


Locations
United States, Maryland
Johns Hopkins Medical Institution
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer Research Foundation
Investigators
Principal Investigator: Kala Visvanathan, MD Johns Hopkins Bloomberg School of Public Health and Sidney Kimmel Comprehensive Cancer Center

Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT00982319     History of Changes
Other Study ID Numbers: J0822
First Posted: September 23, 2009    Key Record Dates
Results First Posted: July 31, 2018
Last Update Posted: July 31, 2018
Last Verified: July 2018

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
Broccoli Sprout Extract
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Sulforafan
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents